3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
113
Lymphoma, Mantle-Cell
65
Lymphoma, Large B-Cell, Diffuse
40
Lymphoma, Non-Hodgkin
31
Lymphoma, Follicular
30
Waldenstrom Macroglobulinemia
29
Lymphoma
29
Lymphoma, B-Cell
22
Recurrence
21
Lymphoma, B-Cell, Marginal Zone
19
Neoplasms
16
Leukemia
14
Leukemia, B-Cell
10
Multiple Myeloma
9
Bronchiolitis Obliterans Syndrome
9
Leukemia, Lymphoid
8
Burkitt Lymphoma
8
Hematologic Neoplasms
7
Leukemia, Myeloid, Acute
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Hodgkin Disease
5
Leukemia, Prolymphocytic
4
Graft vs Host Disease
4
Lymphoproliferative Disorders
3
Lymphatic Diseases
3
Leukemia, Hairy Cell
3
Immunoproliferative Disorders
3
Immune System Diseases
3
Hematologic Diseases
3
Chromosome 17 deletion
3
Interventions
Radiotherapy
119
Temozolomide
109
Carboplatin
52
Filgrastim
46
Vincristine
42
Etoposide
39
Cyclophosphamide
36
Chemotherapy, Adjuvant
36
Cisplatin
35
Carmustine
32
Irinotecan
27
Peripheral Blood Stem Cell Transplantation
25
Magnetic Resonance Spectroscopy
23
Lomustine
22
Thiotepa
21
Methotrexate
19
Granulocyte Colony-Stimulating Factor
18
Procarbazine
16
Bevacizumab
16
Surgical Procedures, Operative
15
O(6)-benzylguanine
14
etoposide phosphate
13
Topotecan
12
Paclitaxel
12
Ifosfamide
12
Drug Therapy
12
Thalidomide
11
Radiation
11
sargramostim
10
Erlotinib Hydrochloride
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Central Nervous System Neoplasms
×
ibrutinib
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled